Dysesthesia: A New Signal for Retatrutide The TRIUMPH-4 Phase 3 trial revealed an unexpected finding: dysesthesia (abnormal touch sensations where normal sensations feel unusual or painful) in 20.9% of participants on 12 mg and 8.8% on 9 mg, compared to 0.7% on placebo (BioSpace, Dec 2025)
Administering an MC1R agonist when receptor expression is lowest
On the other hand, employers that exclude coverage entirely may face pushback from employees, retention challenges, and potential compliance concerns if the exclusion has unintended impacts
Additionally, GlyNAC supplementation resulted in the upregulation of mitophagy and Pax7 expression, as well as downregulation of 8-OHdG, p16INK4, and Muscle POT1 expression, respectively indicating the impacts on loss of proteostasis, stem-cell exhaustion, genomic damage, cellular senescence, and telomere attrition
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
The peptide has demonstrated effectiveness in healing muscle, tendon, ligament, bone, and even neural tissue, making it valuable for diverse surgical applications
